Abstract P5-07-19: A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in Human Epidermal Growth Factor Receptor 2 positive (HER2+) early breast cancer (EBC) in China: NER-Tree study—An interim analysis on safety
Jin Zhang(University of California San Diego), Xiaojia Wang(Wenzhou Medical University), Jundong Wu(Shantou University), Zhaofeng Niu, Jinhui Ye(The First People's Hospital of Zhaoqing), Mopei Wang, Antai Zhang(Guangdong Province Women and Children Hospital), Huanying Zhen(Central South University), Yuanqi Zhang(Guangdong Medical College), Xinlan Liu(Yunnan Agricultural University), Dong Eun Song(Ulsan College), Haiguang Liu(Arizona State University), Shuqun Zhang(Nanjing Agricultural University), Guoqin Jiang(Soochow University), Yiding Chen, Yongsheng Wang(Xihua University), Qiang Zhang(Northwestern University), Hongwei Zhang(Capital Medical University), Jie Wang(Shenzhen University), Suisheng Yang, Xinhong Wu, Jie Ma, Jianxia Liu(Minzu University of China), Quchang Ouyang(Hunan Cancer Hospital), Jidong Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Shihui Ma, Fuguo Tian
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
|Signal Transduction and Targeted Therapy|2021|909
Lipidic cubic phase injector facilitates membrane protein serial femtosecond crystallography
|Nature Communications|2014|596